Research letter
MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+
F. Barataa,
, H. Queirogab, E. Teixeirac, M.T. Almodovard, B. Parentee, M. Soaresf
Corresponding author
a Assistente Hospitalar Graduado de Pneumologia, Centro Hospitalar e Universitário de Coimbra, Portugal
b Professor da Faculdade de Medicina do Porto, Assistente Hospitalar Sénior, Centro Hospitalar de S João, Portugal
c Assistente Hospitalar Graduada de Pneumologia, Centro Hospitalar Lisboa Norte, Portugal
d Assistente Hospitalar Graduada Pneumologia, Instituto Português Oncologia Lisboa Francisco Gentil, Rua Professor Lima, Basto, 1089 Lisboa, Portugal
e Assistente Hospitalar Sénior de Pneumologia, Centro Hospitalar Gaia/Espinho, Portugal
f Assistente Hospitalar de Oncologia Médica, IPOPORTOFG, Portugal
Read
1668
Timeswas read the article
891
Total PDF
777
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 10 | 5 | 15 |
| 2025 5 | 79 | 47 | 126 |
| 2025 4 | 64 | 42 | 106 |
| 2025 3 | 49 | 31 | 80 |
| 2025 2 | 36 | 41 | 77 |
| 2025 1 | 25 | 43 | 68 |
| 2024 12 | 21 | 37 | 58 |
| 2024 11 | 41 | 49 | 90 |
| 2024 10 | 40 | 29 | 69 |
| 2024 9 | 32 | 26 | 58 |
| 2024 8 | 38 | 40 | 78 |
| 2024 7 | 32 | 36 | 68 |
| 2024 6 | 29 | 25 | 54 |
| 2024 5 | 30 | 51 | 81 |
| 2024 4 | 27 | 38 | 65 |
| 2024 3 | 22 | 35 | 57 |
| 2024 2 | 30 | 32 | 62 |
| 2024 1 | 24 | 33 | 57 |
| 2023 12 | 17 | 38 | 55 |
| 2023 11 | 21 | 34 | 55 |
| 2023 10 | 24 | 45 | 69 |
| 2023 9 | 19 | 29 | 48 |
| 2023 8 | 9 | 19 | 28 |
| 2023 7 | 20 | 28 | 48 |
| 2023 6 | 13 | 27 | 40 |
| 2023 5 | 16 | 22 | 38 |
| 2023 4 | 9 | 9 | 18 |
Show all
